The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest

The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia

(2016) Jennifer R. Brown   SEMINARS IN ONCOLOGY

Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment

(2015) Antonino Carbone et al.   JOURNAL OF PATHOLOGY

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Brentuximab Vedotin

(2012) C. Deng et al.   CLINICAL CANCER RESEARCH

Brentuximab Vedotin and Panobinostat: New Drugs for Hodgkin's Lymphoma—Can They Make One of Medical Oncology's Chemotherapy Success Stories More Successful?

(2012) George P. Canellos   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K  inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

(2011) S. A. Meadows et al.   BLOOD

PI3-K and GSK-3: Akt-ing together with microtubules

(2011) Graham J. Buttrick et al.   CELL CYCLE

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Beyond chemotherapy: new agents for targeted treatment of lymphoma

(2010) Anas Younes   Nature Reviews Clinical Oncology